Celldex Therapeutics Inc (CLDX)

Feb 01, 2025

Celldex Therapeutics' (CLDX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Feb 01, 2025

Jan 31, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World

Jan 31, 2025

Jan 31, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India

Jan 31, 2025

Jan 30, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN

Jan 30, 2025

Jan 29, 2025

Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga

Jan 29, 2025

Jan 29, 2025

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jan 29, 2025

Jan 23, 2025

Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Cantor Fitzgerald Predicts CLDX FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 22, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Jan 22, 2025

Jan 22, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 22, 2025

Jan 20, 2025

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat

Jan 20, 2025

Jan 16, 2025

Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register

Jan 16, 2025

Jan 15, 2025

B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR

Jan 15, 2025

Jan 14, 2025

Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa

Jan 14, 2025

Jan 14, 2025

Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India

Jan 14, 2025

Jan 13, 2025

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat

Jan 13, 2025

Jan 08, 2025

Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada

Jan 08, 2025

Jan 08, 2025

Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights

Jan 08, 2025

Jan 08, 2025

Guggenheim maintains $90 target on Celldex stock after study By Investing.com - Investing.com Canada

Jan 08, 2025

Jan 08, 2025

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap UpHere's Why - MarketBeat

Jan 08, 2025

Jan 08, 2025

Before You Invest, Make Sure You Check This Asset Entities Inc (NASDAQ: ASST) Analysis - Stocks Register

Jan 08, 2025

Jan 08, 2025

What Do Wall Street Analysts Think About Celldex Therapeutics Inc (NASDAQ: CLDX) Stock? - Stocks Register

Jan 08, 2025

Jan 08, 2025

Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga

Jan 08, 2025

Jan 08, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Nigeria

Jan 07, 2025

Jan 07, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook - Investing.com India

Jan 07, 2025

Jan 03, 2025

Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Jan 03, 2025

Jan 02, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com Nigeria

Jan 02, 2025

Jan 02, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com South Africa

Jan 02, 2025

Jan 02, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India

Jan 02, 2025

Jan 02, 2025

Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Jan 02, 2025

Jan 01, 2025

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Drops By 5.1% - MarketBeat

Jan 01, 2025

Dec 28, 2024

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 28, 2024

Dec 28, 2024

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Dec 28, 2024

Dec 22, 2024

Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Dec 22, 2024

Dec 20, 2024

What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga

Dec 20, 2024

Dec 19, 2024

Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 19, 2024

Dec 19, 2024

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times

Dec 19, 2024

Dec 19, 2024

Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan

Dec 19, 2024

Dec 17, 2024

State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Dec 17, 2024

Dec 16, 2024

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Nigeria

Dec 16, 2024

Dec 14, 2024

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.5%Here's Why - MarketBeat

Dec 14, 2024

Dec 11, 2024

BNP Paribas Financial Markets Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Dec 11, 2024

Dec 09, 2024

XTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Dec 09, 2024